This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
by Zacks Equity Research
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch
by Zacks Equity Research
Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch are part of the Zacks top Analyst Blog.
Top Stock Reports for NIKE, Novartis & Wells Fargo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Novartis AG (NVS) and Wells Fargo & Company (WFC).
Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.
Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
by Zacks Equity Research
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
by Zacks Equity Research
Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.
The Zacks Analyst Blog Highlights Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment
by Zacks Equity Research
Amazon.com, Novartis, Philip Morris International, Automatic Data Processing and Live Nation Entertainment are part of the Zacks top Analyst Blog.
Top Analyst Reports for Amazon.com, Novartis & Philip Morris
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Novartis AG (NVS) and Philip Morris International Inc. (PM).
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
by Kinjel Shah
Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
by Zacks Equity Research
Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.
Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates
by Kinjel Shah
A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.
Novartis' (NVS) PNH Candidate Achieves Study Objectives
by Zacks Equity Research
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
by Zacks Equity Research
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
Novartis (NVS) Reportedly Looking to Sell Its Business Units
by Zacks Equity Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
by Zacks Equity Research
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
by Zacks Equity Research
ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022